{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:43:31Z","timestamp":1760489011885,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94587","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T20:47:13Z","timestamp":1760474833000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Time to Diagnosis of Secondary Malignancies Among Patients With Hairy Cell Leukemia: A Systematic Review and Meta-analysis"],"prefix":"10.7759","author":[{"given":"Akihiro","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasawee","family":"Tanariyakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chalothorn","family":"Wannaphut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakditad","family":"Saowapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00980-X","article-title":"Advances in the treatment of hairy-cell leukaemia","volume":"4","author":"Mey U","year":"2003","unstructured":"Mey U, Strehl J, Gorschl\u00fcter M, Ziske C, Glasmacher A, Pralle H, Schmidt-Wolf I. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol. 2003, 4:86-94. 10.1016\/S1470-2045(03)00980-X","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1608536","article-title":"Hairy cell leukemia: present and future directions","volume":"60","author":"Kreitman RJ","year":"2019","unstructured":"Kreitman RJ. Hairy cell leukemia: present and future directions. Leuk Lymphoma. 2019, 60:2869-79. 10.1080\/10428194.2019.1608536","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else M","year":"2009","unstructured":"Else M, Dearden CE, Matutes E, et al.. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009, 145:733-40. 10.1111\/j.1365-2141.2009.07668.x","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01546.x","article-title":"Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine","volume":"106","author":"Dearden CE","year":"1999","unstructured":"Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol. 1999, 106:515-9. 10.1046\/j.1365-2141.1999.01546.x","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0328-z","article-title":"Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up","volume":"10","author":"Paillassa J","year":"2020","unstructured":"Paillassa J, Cornet E, Noel S, et al.. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020, 10:62. 10.1038\/s41408-020-0328-z","journal-title":"Blood Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven A","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998, 92:1918-26. 10.1182\/blood.V92.6.1918","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1160","article-title":"Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience","volume":"92","author":"Au WY","year":"1998","unstructured":"Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood. 1998, 92:1160-4. 10.1182\/blood.V92.4.1160","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else M","year":"2015","unstructured":"Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015, 28:217-29. 10.1016\/j.beha.2015.09.004","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12908","article-title":"Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia","volume":"166","author":"Cornet E","year":"2014","unstructured":"Cornet E, Tomowiak C, Tanguy-Schmidt A, et al.. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014, 166:390-400. 10.1111\/bjh.12908","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","unstructured":"The Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2014). Accessed: September 25, 2025:  https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo D","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018, 27:1785-805. 10.1177\/0962280216669183","journal-title":"Stat Methods Med Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002160","article-title":"Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial","volume":"4","author":"Benz R","year":"2020","unstructured":"Benz R, Arn K, Andres M, et al.. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv. 2020, 4:3699-707. 10.1182\/bloodadvances.2020002160","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v16i4.10878","article-title":"Retrospective evaluation of hairy cell leukemia patients: analysis of a long-term single center data","volume":"16","author":"Biglari M","year":"2022","unstructured":"Biglari M, Kamranzadeh Foumani H, Bagherian M, Chahardouli B, Ghavamzadeh A. Retrospective evaluation of hairy cell leukemia patients: analysis of a long-term single center data. Int J Hematol Oncol Stem Cell Res. 2022, 16:209-16. 10.18502\/ijhoscr.v16i4.10878","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081475","article-title":"Second neoplasms in Italian patients with hairy cell leukemia after treatment with cladribine: a multicenter investigation and literature review","volume":"16","author":"Criscuolo M","year":"2024","unstructured":"Criscuolo M, Tosti ME, Broccoli A, et al.. Second neoplasms in Italian patients with hairy cell leukemia after treatment with cladribine: a multicenter investigation and literature review. Cancers (Basel). 2024, 16:1475. 10.3390\/cancers16081475","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.638","article-title":"Risk of second cancer in patients with hairy cell leukemia: long-term follow-up","volume":"20","author":"Federico M","year":"2002","unstructured":"Federico M, Zinzani PL, Frassoldati A, et al.. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol. 2002, 20:638-46. 10.1200\/JCO.2002.20.3.638","journal-title":"J Clin Oncol"},{"key":"ref18","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn IW","year":"2000","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, et al.. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000, 96:2981-6.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14207","article-title":"Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia","volume":"175","author":"Getta BM","year":"2016","unstructured":"Getta BM, Woo KM, Devlin S, et al.. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol. 2016, 175:402-9. 10.1111\/bjh.14207","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman GR","year":"2003","unstructured":"Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003, 21:891-6. 10.1200\/JCO.2003.05.093","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study","volume":"99","author":"Hisada M","year":"2007","unstructured":"Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007, 99:215-22. 10.1093\/jnci\/djk030","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1803","article-title":"Second cancer risk in hairy cell leukemia: analysis of 350 patients","volume":"15","author":"Kurzrock R","year":"1997","unstructured":"Kurzrock R, Strom SS, Estey E, et al.. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997, 15:1803-10. 10.1200\/JCO.1997.15.5.1803","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.003","article-title":"Long-term outcomes of hairy cell leukemia treated with purine analogs: a comparison with the general population","volume":"17","author":"Madanat YF","year":"2017","unstructured":"Madanat YF, Rybicki L, Radivoyevitch T, et al.. Long-term outcomes of hairy cell leukemia treated with purine analogs: a comparison with the general population. Clin Lymphoma Myeloma Leuk. 2017, 17:857-62. 10.1016\/j.clml.2017.07.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients","volume":"17","author":"Maloisel F","year":"2003","unstructured":"Maloisel F, Benboubker L, Gardembas M, et al.. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003, 17:45-51. 10.1038\/sj.leu.2402784","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg JD","year":"2014","unstructured":"Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014, 123:177-83. 10.1182\/blood-2013-06-508754","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.06.001","article-title":"Outcomes and second neoplasms in hairy cell leukemia: a retrospective cohort","volume":"83","author":"da Silva WF","year":"2019","unstructured":"da Silva WF, Neto AC, da Rosa LI, et al.. Outcomes and second neoplasms in hairy cell leukemia: a retrospective cohort. Leuk Res. 2019, 83:106165. 10.1016\/j.leukres.2019.06.001","journal-title":"Leuk Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson BD","year":"1995","unstructured":"Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995, 13:2431-48. 10.1200\/JCO.1995.13.9.2431","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.570819","article-title":"Infectious complications in hairy cell leukemia","volume":"52 Suppl 2","author":"Kraut E","year":"2011","unstructured":"Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011, 52 Suppl 2:50-2. 10.3109\/10428194.2011.570819","journal-title":"Leuk Lymphoma"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811862","article-title":"Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma","volume":"61","author":"Chinen Y","year":"2020","unstructured":"Chinen Y, Tanba K, Takagi R, et al.. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leuk Lymphoma. 2020, 61:3378-86. 10.1080\/10428194.2020.1811862","journal-title":"Leuk Lymphoma"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409056295","article-title":"Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for hairy cell leukemia","volume":"13","author":"Frassoldati A","year":"1994","unstructured":"Frassoldati A, Lamparelli T, Federico M, et al.. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for hairy cell leukemia. Leuk Lymphoma. 1994, 13:307-16. 10.3109\/10428199409056295","journal-title":"Leuk Lymphoma"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph9072444","article-title":"Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor","volume":"9","author":"Ezoe S","year":"2012","unstructured":"Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012, 9:2444-53. 10.3390\/ijerph9072444","journal-title":"Int J Environ Res Public Health"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00702-9","article-title":"Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study","volume":"12","author":"Pagano L","year":"2022","unstructured":"Pagano L, Criscuolo M, Broccoli A, et al.. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer J. 2022, 12:109. 10.1038\/s41408-022-00702-9","journal-title":"Blood Cancer J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever MR","year":"2010","unstructured":"Grever MR. How I treat hairy cell leukemia. Blood. 2010, 115:21-8. 10.1182\/blood-2009-06-195370","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416667-incidence-and-time-to-diagnosis-of-secondary-malignancies-among-patients-with-hairy-cell-leukemia-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T20:47:14Z","timestamp":1760474834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416667-incidence-and-time-to-diagnosis-of-secondary-malignancies-among-patients-with-hairy-cell-leukemia-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.94587","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}